Kalpit Patel
Stock Analyst at B. Riley Securities
(1.56)
# 3,505
Out of 5,150 analysts
71
Total ratings
38.78%
Success rate
-6.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Buy | $80 → $117 | $86.11 | +35.87% | 6 | Dec 22, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $5 → $3 | $0.70 | +328.57% | 6 | Nov 25, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Peer Perform | n/a | $13.51 | - | 1 | Nov 18, 2025 | |
| CORT Corcept Therapeutics | Initiates: Peer Perform | n/a | $35.69 | - | 1 | Nov 18, 2025 | |
| JANX Janux Therapeutics | Initiates: Peer Perform | n/a | $14.35 | - | 1 | Nov 18, 2025 | |
| TNGX Tango Therapeutics | Initiates: Peer Perform | n/a | $12.35 | - | 1 | Nov 18, 2025 | |
| ACLX Arcellx | Initiates: Peer Perform | n/a | $114.30 | - | 1 | Nov 18, 2025 | |
| SMMT Summit Therapeutics | Initiates: Peer Perform | n/a | $15.38 | - | 1 | Nov 18, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Outperform | $42 | $47.43 | -11.45% | 1 | Nov 18, 2025 | |
| SLNO Soleno Therapeutics | Initiates: Outperform | $75 | $38.13 | +96.70% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $101.19 | -25.88% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $110 | $112.18 | -1.94% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $12 | $8.04 | +49.25% | 6 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $14 | $5.63 | +148.67% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $26.56 | +39.31% | 1 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $24 | $29.63 | -19.00% | 6 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5.5 → $3.5 | $1.47 | +138.10% | 4 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $5.81 | +54.91% | 4 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.67 | +76.37% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $40 | $8.42 | +375.06% | 2 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $1.68 | +78.57% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $30.39 | -34.19% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $3.50 | +757.14% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $21.62 | +66.51% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $90 | $1.73 | +5,102.31% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $2.53 | +611.46% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.30 | +284.62% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $10.91 | +816.59% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $31.76 | +136.15% | 2 | Sep 3, 2021 |
Kymera Therapeutics
Dec 22, 2025
Maintains: Buy
Price Target: $80 → $117
Current: $86.11
Upside: +35.87%
PDS Biotechnology
Nov 25, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $0.70
Upside: +328.57%
ORIC Pharmaceuticals
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $13.51
Upside: -
Corcept Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $35.69
Upside: -
Janux Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $14.35
Upside: -
Tango Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $12.35
Upside: -
Arcellx
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $114.30
Upside: -
Summit Therapeutics
Nov 18, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $15.38
Upside: -
Scholar Rock Holding
Nov 18, 2025
Initiates: Outperform
Price Target: $42
Current: $47.43
Upside: -11.45%
Soleno Therapeutics
Nov 18, 2025
Initiates: Outperform
Price Target: $75
Current: $38.13
Upside: +96.70%
Nov 18, 2025
Initiates: Outperform
Price Target: $75
Current: $101.19
Upside: -25.88%
Nov 18, 2025
Initiates: Outperform
Price Target: $110
Current: $112.18
Upside: -1.94%
Jul 30, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $8.04
Upside: +49.25%
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $5.63
Upside: +148.67%
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $26.56
Upside: +39.31%
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $29.63
Upside: -19.00%
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.47
Upside: +138.10%
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $5.81
Upside: +54.91%
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $5.67
Upside: +76.37%
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $8.42
Upside: +375.06%
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $1.68
Upside: +78.57%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $30.39
Upside: -34.19%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $3.50
Upside: +757.14%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $21.62
Upside: +66.51%
Nov 11, 2022
Downgrades: Neutral
Price Target: $270 → $90
Current: $1.73
Upside: +5,102.31%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $2.53
Upside: +611.46%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.30
Upside: +284.62%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $10.91
Upside: +816.59%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $31.76
Upside: +136.15%